Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Regulatory Science

Background:

• Solid oral modified release (MR) drug products require rigorous development to ensure consistent therapeutic outcomes.
• Patient-focused development using Quality-by-Design (QbD) principles is crucial for optimizing MR product performance.
• Understanding the interplay between material attributes, process parameters, and quality attributes is essential for predictable clinical performance.

Purpose of the Study:

• To present scientific and regulatory considerations for developing solid oral MR drug products.
• To highlight the importance of QbD principles in patient-focused MR product development.
• To emphasize the role of biopharmaceutics tools in linking critical quality attributes (CQAs) to clinical performance.

Main Methods:

• Identification and risk-based evaluation of critical material attributes (CMAs) and critical process parameters (CPPs).
• Assessment of the impact of CMAs and CPPs on critical quality attributes (CQAs) affecting clinical performance.
• Application of biopharmaceutics tools to establish a link between CQAs and predictable clinical performance.

Main Results:

• Product and process understanding facilitate the development of comprehensive control strategies for MR products.
• Risk-based evaluation of CMAs and CPPs helps mitigate the probability of CQA failures.
• Biopharmaceutics tools enable the prediction and reproducibility of clinical performance based on CQAs.

Conclusions:

• A thorough understanding of product and process is key to developing robust control strategies for MR drug products.
• Implementing QbD principles and biopharmaceutics tools enhances the consistency and safety of MR products.
• The goal is to ensure MR products consistently meet clinical objectives while minimizing patient risks through effective quality control.